Coastal Bridge Advisors LLC Acquires New Position in Stryker Corporation $SYK

Coastal Bridge Advisors LLC bought a new position in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,573 shares of the medical technology company’s stock, valued at approximately $810,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Gables Capital Management Inc. bought a new stake in Stryker during the 2nd quarter valued at $25,000. Kilter Group LLC purchased a new position in shares of Stryker during the second quarter valued at $25,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter valued at $26,000. Sankala Group LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Finally, Compass Financial Management LLC bought a new stake in shares of Stryker in the second quarter valued at about $27,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $322.20 on Friday. The firm has a market capitalization of $123.58 billion, a PE ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The business’s 50-day moving average is $328.64 and its two-hundred day moving average is $331.47. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the firm posted $3.13 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on SYK shares. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. UBS Group started coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.